Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2231-2239

  Chen, Yun ^a,b   Tsai, Ya Hui ^a,b   Tseng, Sheng Hong ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Celecoxib; Cytotoxicity; Neuroblastoma; Valproic acid

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; STRATIFIN; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; G0 PHASE; G1 PHASE; HUMANS; NEUROBLASTOMA; PYRAZOLES; SULFONAMIDES; VALPROIC ACID;

EID: 79960449969     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Park JR, Eggert A and Caron H: Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 55: 97-120, 2008.
2. Hrebackova J, Hrabeta J and Eckschlager T: Valproic acid in the complex therapy of malignant tumors. Curr Drug Therapy 11: 361-379, 2010.
3. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M and Ottmann OG: Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104: 2717-2725, 2005. (Pubitemid 41798282)
4. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A and Fruhwald MC: Inhibitors of histone deacetylase as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 120: 1787-1794, 2007. (Pubitemid 46399367)
5. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S and Cortes J: Phase 1/2 study of the combination of 5-aza-2′-deoxycytodine with valproic acid in patients with leukemia. Blood 108: 3271-3279, 2006.
6. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H and Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106: 112-119, 2006.
7. Munster P, Marchion D, Bicaku E, Springen G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM and Daud AI: Phase 1 trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25: 1979-1985, 2007.
8. Stockhausen MT, Sjolund J, Manetopoulos C and Axelson H: Effects of the histone deacetylase inhibitor valproic acid on Notch signaling in human neuroblastoma cells. Br J Cancer 92: 751-759, 2005. (Pubitemid 40460614)
9. Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J and Cohn SL: Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 67: 1716-1724, 2007. (Pubitemid 46383398)
10. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M and Chen H: Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12: 942-951, 2007. (Pubitemid 47359136)
11. INK4A up-regulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther 6: 185-191, 2007. (Pubitemid 46641621)
12. Takai N, Desmond JC, Kumagai T, Gui D, Sais JW, Whittaker S, Miyakawa I and Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004. (Pubitemid 38198916)
13. Liu H, Huang P, Xu X, Liu J and Guo C: Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancer cells. Dig Dis Sci 54: 1418-1424, 2009.
14. Jendrossek V: Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett 2011.
15. Chen JC, Chen Y, Su YH and Tseng SH: Celecoxib increased expression of 14-3-3σ and induced apoptosis of glioma cells. Anticancer Res 27: 2547-2554, 2007. (Pubitemid 47232274)
16. Ponthan F, Wickstrom M, Gleissman H, Fuskevåg OM, Segerström L, Sveinbjörnsson B, Redfern CP, Eksborg S, Kogner P and Johnsen JI: Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13: 1036-1044, 2007. (Pubitemid 46340383)
17. Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schönthal AH: Down-regulation of surviving expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2 inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5: 19, 2006.
18. Cui W, Hu SX, Tang ZY and Hu KQ: In vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs 19: 891-897, 2008.
19. Lau LM, Wolter JK, Lau JT, Cheng LS, Smith KM, Hansford LM, Zhang L, Baruchel S, Robinson F and Irwin MS: Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28: 2024-2033, 2009.
20. Ghsoh N, Vhaki R, Mandai V and Mandai SC: COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62: 233-244, 2010.
21. Xiao H, Zhang Q, Lin Y, Reddy BS and Yang CS: Combination of atorvastin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122: 2115-2124, 2008. (Pubitemid 351441204)
22. Kaneko M, Kaneko S and Suzuki K: Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Sci 100: 2193-2201, 2009.
23. Cao D, Bromberg PA and Samet JM: COX2 expression induced by Diesel particles involves chromatin modification and degradation of HDAC1. Am J Respir Cell Mol Biol 37: 232-239, 2007. (Pubitemid 47255006)
24. Choi YH: Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol 27: 473-379, 2005.
25. Tong M, Ding Y and Tai HH: Histone deacetylase inhibitors and transforming growth factor- induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol 72: 701-709, 2006. (Pubitemid 44233546)
26. Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A, Suzuki H, Hayashizaki Y, Hume DA, Sweet MJ and Ravasi T: LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J 20: 1315-1327, 2006. (Pubitemid 44943839)
27. Yamauchi J, Miyamoto Y, Murabe M, Fujiwara Y, Sanbe A, Fujita Y, Murase S and Tanoue A: Gadd45a, the gene induced by the mood stabilizer valproic acid, regulates neurite outgrowth through JNK and the substrate paxillin in N1E-115 neuroblastoma cells. Exp Cell Res 313: 1886-1896, 2007.
28. Kikuchi T, Itoh F, Toyata M, Suzuki H, Yamamoto H, Fujita M, Hosokawa M and Imai K: Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer. Int J Cancer 97: 272-277, 2002. (Pubitemid 34049015)
29. 2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42: 422-426, 2006. (Pubitemid 43132900)
30. Mazzanti R, Platini F, Bottini C, Fantappiè O, Solazzo M and Tessitore L: Down- regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. Biochem Pharmacol 78: 21-32, 2009.
31. Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, Haferkamp A and Blaheta RA: Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 88: 418-424, 2011.
32. 1 phase. J Neurochem 83: 12-19, 2002.
33. Chang JK, Li CJ, Liao HJ, Wang CK, Wang GJ and Ho ML: Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology 258: 148-156, 2009.
34. Eckerle I, Muth D, Batzier J, Henrich KO, Lutz W, Fischer M, Witt O, Schwab M and Westermann F: Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett 285: 99-107, 2009.
35. Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M and Cleveland JL: Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69: 547-553, 2009.
36. Belletti B, Nicoloso MS, Schiappacassi M, Chimienti E, Berton S, Lovat F, Colombatti A and Baldassarre G: p27 (kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem 12: 1589-1605, 2005. (Pubitemid 40895003)
37. Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T and Sasaki K: Expression of p21 (WAF1/CIP1) and p53 proteins in gastric carcinomas: its relationships with cell proliferation activity and prognosis. Cancer Lett 170: 183-189, 2001. (Pubitemid 32709919)
38. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
39. Kitagawa K, Kotake Y and Kitagawa M: Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci 100: 1374-1381, 2009.
40. Creason TK, Yuan P, Manji HK and Chen G: Evidence for involvement of ERK, PI3K, and RSK in induction of BCL-2 by valproate. J Mol Neurosci 37: 123-134, 2008.
41. Sung ES, Kim A, Park JS, Chung J, Kwon MH and Kim YS: Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 15: 1256-1269, 2010.
42. Yagi Y, Fushida S, Harada S, Kinoshita J, Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, Fujimura T, Ohta T, Yashiro M and Hirakawa K: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 29: 149, 2010.